New shot aims to cure chronic hepatitis b – early trial underway
NCT ID NCT06550128
First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be able to stop their daily medication. Participants receive injections of AHB-137 or a placebo over several weeks, and researchers monitor safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AHB-137 injection
- What this could lead to
- If successful, this could point toward a functional cure for chronic hepatitis B, allowing patients to stop long-term antiviral medication.
- What could go wrong
- This is an early Phase 2 trial with only 86 participants. The drug may not achieve sustained viral clearance, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
The First Hospital of Jilin University
Jilin City, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
-
The third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data